Effect of losartan and hydrochlorothiazide on exercise tolerance in exertional hypertension and left ventricular

William C Little1, Michael R Zile, Allan Klein

  • 1Cardiology Section, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. wlittle@wfubmc.edu

Insights

Losartan and hydrochlorothiazide (HCTZ) both reduced exercise systolic blood pressure in patients with diastolic dysfunction. However, only losartan improved exercise tolerance and quality of life.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Left ventricular diastolic dysfunction is characterized by impaired relaxation and filling of the left ventricle.
  • Hypertensive response to exercise, defined as elevated systolic blood pressure during physical activity, is a significant clinical finding.

Purpose of the Study:

  • To compare the efficacy of losartan versus hydrochlorothiazide (HCTZ) in managing exercise-induced hypertension in patients with diastolic dysfunction.
  • To assess the impact of these treatments on exercise capacity and quality of life.

Main Methods:

  • A randomized, double-blind study involving 40 subjects with specific criteria for diastolic dysfunction and exercise systolic blood pressure.
  • Participants received either losartan 50 mg or HCTZ 12.5 mg daily for six months.
  • Evaluations included resting and exercise blood pressure, treadmill exercise time, quality of life scores, and oxygen consumption.

Main Results:

  • Both losartan and HCTZ effectively reduced exercise systolic blood pressure.
  • Losartan significantly increased treadmill exercise time and improved quality of life without altering oxygen consumption.
  • HCTZ did not significantly change exercise time or quality of life and led to a decrease in oxygen consumption.

Conclusions:

  • In patients with diastolic dysfunction and hypertensive response to exercise, both losartan and HCTZ can blunt exercise systolic blood pressure.
  • Losartan demonstrates superior benefits by enhancing exercise tolerance and improving quality of life compared to HCTZ in this patient population.

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...